Comparative Pharmacology
Head-to-head clinical analysis: MOTRIN IB versus MOTRIN MIGRAINE PAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTRIN IB versus MOTRIN MIGRAINE PAIN.
MOTRIN IB vs MOTRIN MIGRAINE PAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.
Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.8–2.5 hours) in adults. In patients with hepatic impairment or advanced age, half-life may be prolonged. The short half-life supports dosing every 6–8 hours for analgesia.
2 hours (1.5-2.5 h in adults; prolonged in elderly and renal impairment).
Renal excretion of conjugated metabolites (primarily glucuronide and sulfate) accounts for approximately 90% of an absorbed dose; less than 1% is excreted unchanged. Biliary/fecal elimination constitutes about 10%.
Renal: 90% (metabolites and unchanged, 10-20% unchanged). Biliary/Fecal: <5%.
Category C
Category C
NSAID Analgesic
NSAID Analgesic